Biomerica, Inc. Logo

Biomerica, Inc.

BMRA

(1.0)
Stock Price

0,35 USD

-66.11% ROA

-69.21% ROE

-0.89x PER

Market Cap.

5.332.447,00 USD

11.91% DER

0% Yield

-110.44% NPM

Biomerica, Inc. Stock Analysis

Biomerica, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Biomerica, Inc. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (9%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 PBV

The stock's PBV ratio (1.44x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

3 Graham Number

Based on the Graham number, this company's stock price appears to be lower than its intrinsic value, signaling a potentially favorable investment choice.

4 ROE

The stock's ROE indicates a negative return (-69.43%) on shareholders' equity, suggesting poor financial performance.

5 ROA

The stock's ROA (-47.63%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

7 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (-1) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

Biomerica, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Biomerica, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Sell
4 Stoch RSI Sell

Biomerica, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Biomerica, Inc. Revenue
Year Revenue Growth
1986 1.700.000
1987 1.900.000 10.53%
1988 1.400.000 -35.71%
1989 1.200.000 -16.67%
1990 8.200.000 85.37%
1991 10.400.000 21.15%
1992 7.800.000 -33.33%
1993 8.000.000 2.5%
1994 8.300.000 3.61%
1995 9.200.000 9.78%
1996 9.500.000 3.16%
1997 9.200.000 -3.26%
1998 9.400.000 2.13%
1999 8.700.000 -8.05%
2000 8.033.708 -8.29%
2001 8.939.522 10.13%
2002 8.598.054 -3.97%
2003 9.059.938 5.1%
2004 9.168.833 1.19%
2005 9.273.980 1.13%
2006 7.184.992 -29.07%
2007 5.748.319 -24.99%
2008 4.926.505 -16.68%
2009 4.934.771 0.17%
2010 5.075.222 2.77%
2011 4.899.375 -3.59%
2011 4.899.375 0%
2012 6.081.131 19.43%
2013 6.472.960 6.05%
2014 5.120.451 -26.41%
2015 4.962.373 -3.19%
2016 5.139.816 3.45%
2017 5.791.670 11.26%
2018 5.564.185 -4.09%
2019 5.200.682 -6.99%
2020 6.692.711 22.29%
2021 7.199.027 7.03%
2022 18.871.409 61.85%
2023 5.339.000 -253.46%
2024 4.464.000 -19.6%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Biomerica, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1986 0
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 300.000 100%
1996 300.000 0%
1997 300.000 0%
1998 600.000 50%
1999 500.000 -20%
2000 898.122 44.33%
2001 322.121 -178.82%
2002 159.758 -101.63%
2003 262.841 39.22%
2004 273.981 4.07%
2005 274.288 0.11%
2006 239.004 -14.76%
2007 256.101 6.68%
2008 259.085 1.15%
2009 278.308 6.91%
2010 455.171 38.86%
2011 420.571 -8.23%
2011 420.571 0%
2012 347.128 -21.16%
2013 459.086 24.39%
2014 589.866 22.17%
2015 733.640 19.6%
2016 780.333 5.98%
2017 1.130.635 30.98%
2018 1.398.368 19.15%
2019 1.679.098 16.72%
2020 1.910.209 12.1%
2021 2.410.506 20.75%
2022 1.812.424 -33%
2023 1.584.000 -14.42%
2024 1.060.000 -49.43%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Biomerica, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1986 0
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 14.613 100%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Biomerica, Inc. EBITDA
Year EBITDA Growth
1986 -1.800.000
1987 -1.100.000 -63.64%
1988 -2.500.000 56%
1989 -900.000 -177.78%
1990 800.000 212.5%
1991 -1.100.000 172.73%
1992 -700.000 -57.14%
1993 100.000 800%
1994 600.000 83.33%
1995 800.000 25%
1996 1.000.000 20%
1997 700.000 -42.86%
1998 200.000 -250%
1999 -300.000 166.67%
2000 -4.086.080 92.66%
2001 -522.356 -682.24%
2002 -240.336 -117.34%
2003 -162.862 -47.57%
2004 -251.017 35.12%
2005 -111.417 -125.3%
2006 -20.618 -440.39%
2007 537.486 103.84%
2008 -574.229 193.6%
2009 366.177 256.82%
2010 -235.801 255.29%
2011 313.086 175.32%
2011 313.086 0%
2012 685.123 54.3%
2013 741.474 7.6%
2014 -219.245 438.19%
2015 -393.159 44.24%
2016 -563.398 30.22%
2017 -689.060 18.24%
2018 -1.247.390 44.76%
2019 -2.205.871 43.45%
2020 -1.933.023 -14.12%
2021 -6.079.757 68.21%
2022 -3.912.504 -55.39%
2023 -6.872.000 43.07%
2024 -5.724.000 -20.06%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Biomerica, Inc. Gross Profit
Year Gross Profit Growth
1986 500.000
1987 1.100.000 54.55%
1988 400.000 -175%
1989 400.000 0%
1990 4.200.000 90.48%
1991 3.700.000 -13.51%
1992 3.000.000 -23.33%
1993 3.200.000 6.25%
1994 4.000.000 20%
1995 4.400.000 9.09%
1996 4.400.000 0%
1997 4.000.000 -10%
1998 4.100.000 2.44%
1999 3.600.000 -13.89%
2000 2.631.403 -36.81%
2001 2.809.622 6.34%
2002 2.535.592 -10.81%
2003 2.898.453 12.52%
2004 2.916.416 0.62%
2005 3.085.082 5.47%
2006 2.405.377 -28.26%
2007 2.245.712 -7.11%
2008 2.135.622 -5.15%
2009 1.969.863 -8.41%
2010 1.560.767 -26.21%
2011 1.525.589 -2.31%
2011 1.525.589 0%
2012 2.297.176 33.59%
2013 2.427.861 5.38%
2014 1.669.208 -45.45%
2015 1.541.806 -8.26%
2016 1.524.042 -1.17%
2017 2.021.791 24.62%
2018 1.754.400 -15.24%
2019 1.292.014 -35.79%
2020 1.781.776 27.49%
2021 496.981 -258.52%
2022 2.977.418 83.31%
2023 446.000 -567.58%
2024 80.000 -457.5%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Biomerica, Inc. Net Profit
Year Net Profit Growth
1986 -1.900.000
1987 -1.300.000 -46.15%
1988 -400.000 -225%
1989 -900.000 55.56%
1990 -600.000 -50%
1991 -1.200.000 50%
1992 -900.000 -33.33%
1993 -400.000 -125%
1994 0 0%
1995 100.000 100%
1996 400.000 75%
1997 400.000 0%
1998 100.000 -300%
1999 -100.000 200%
2000 -3.890.849 97.43%
2001 -2.672.318 -45.6%
2002 -420.735 -535.15%
2003 -223.867 -87.94%
2004 -223.201 -0.3%
2005 162.259 237.56%
2006 230.273 29.54%
2007 536.879 57.11%
2008 1.710.044 68.6%
2009 354.180 -382.82%
2010 -331.455 206.86%
2011 157.447 310.52%
2011 157.447 0%
2012 548.435 71.29%
2013 536.957 -2.14%
2014 -215.660 348.98%
2015 -331.410 34.93%
2016 -1.499.787 77.9%
2017 -908.561 -65.07%
2018 -1.465.828 38.02%
2019 -2.393.060 38.75%
2020 -2.339.054 -2.31%
2021 -6.469.036 63.84%
2022 -4.531.044 -42.77%
2023 -7.140.000 36.54%
2024 -5.684.000 -25.62%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Biomerica, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1986 -1
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 -1 0%
2001 -1 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 -1 0%
2022 0 0%
2023 -1 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Biomerica, Inc. Free Cashflow
Year Free Cashflow Growth
1989 -600.000
1990 -400.000 -50%
1991 700.000 157.14%
1992 -500.000 240%
1993 -500.000 0%
1994 900.000 155.56%
1995 300.000 -200%
1996 400.000 25%
1997 500.000 20%
1998 300.000 -66.67%
1999 -500.000 160%
2000 -2.770.186 81.95%
2001 47.036 5989.5%
2002 -142.801 132.94%
2003 276.251 151.69%
2004 -511.121 154.05%
2005 -169.320 -201.87%
2006 -637.597 73.44%
2007 351.013 281.64%
2008 -459.378 176.41%
2009 -217.889 -110.83%
2010 -606.382 64.07%
2011 62.444 1071.08%
2011 62.444 0%
2012 -67.386 192.67%
2013 1.136.916 105.93%
2014 -1.146.003 199.21%
2015 -430.163 -166.41%
2016 -303.974 -41.51%
2017 -818.943 62.88%
2018 -1.304.564 37.22%
2019 -2.415.150 45.98%
2020 -4.416.425 45.31%
2021 -5.547.331 20.39%
2022 -650.868 -752.3%
2023 -5.552.000 88.28%
2024 -1.068.000 -419.85%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Biomerica, Inc. Operating Cashflow
Year Operating Cashflow Growth
1989 -600.000
1990 -200.000 -200%
1991 1.100.000 118.18%
1992 -400.000 375%
1993 -400.000 0%
1994 1.000.000 140%
1995 500.000 -100%
1996 500.000 0%
1997 700.000 28.57%
1998 400.000 -75%
1999 -400.000 200%
2000 -2.563.803 84.4%
2001 108.955 2453.08%
2002 -131.073 183.13%
2003 512.536 125.57%
2004 -75.032 783.09%
2005 72.920 202.9%
2006 -385.169 118.93%
2007 463.708 183.06%
2008 -194.595 338.29%
2009 -101.999 -90.78%
2010 -236.980 56.96%
2011 328.803 172.07%
2011 328.803 0%
2012 147.412 -123.05%
2013 1.394.037 89.43%
2014 -862.273 261.67%
2015 -405.481 -112.65%
2016 -208.782 -94.21%
2017 -722.858 71.12%
2018 -1.174.217 38.44%
2019 -2.244.039 47.67%
2020 -4.297.498 47.78%
2021 -5.251.748 18.17%
2022 -480.532 -992.9%
2023 -5.474.000 91.22%
2024 -1.044.000 -424.33%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Biomerica, Inc. Capital Expenditure
Year Capital Expenditure Growth
1989 0
1990 200.000 100%
1991 400.000 50%
1992 100.000 -300%
1993 100.000 0%
1994 100.000 0%
1995 200.000 50%
1996 100.000 -100%
1997 200.000 50%
1998 100.000 -100%
1999 100.000 0%
2000 206.383 51.55%
2001 61.919 -233.31%
2002 11.728 -427.96%
2003 236.285 95.04%
2004 436.089 45.82%
2005 242.240 -80.02%
2006 252.428 4.04%
2007 112.695 -123.99%
2008 264.783 57.44%
2009 115.890 -128.48%
2010 369.402 68.63%
2011 266.359 -38.69%
2011 266.359 0%
2012 214.798 -24%
2013 257.121 16.46%
2014 283.730 9.38%
2015 24.682 -1049.54%
2016 95.192 74.07%
2017 96.085 0.93%
2018 130.347 26.29%
2019 171.111 23.82%
2020 118.927 -43.88%
2021 295.583 59.77%
2022 170.336 -73.53%
2023 78.000 -118.38%
2024 24.000 -225%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Biomerica, Inc. Equity
Year Equity Growth
1986 6.100.000
1987 4.600.000 -32.61%
1988 4.100.000 -12.2%
1989 3.300.000 -24.24%
1990 4.600.000 28.26%
1991 2.500.000 -84%
1992 2.300.000 -8.7%
1993 2.800.000 17.86%
1994 3.300.000 15.15%
1995 3.200.000 -3.13%
1996 4.100.000 21.95%
1997 5.900.000 30.51%
1998 6.200.000 4.84%
1999 6.200.000 0%
2000 4.907.747 -26.33%
2001 3.519.821 -39.43%
2002 3.295.598 -6.8%
2003 3.245.900 -1.53%
2004 3.513.574 7.62%
2005 3.532.914 0.55%
2006 1.063.747 -232.12%
2007 1.752.552 39.3%
2008 3.883.948 54.88%
2009 4.347.986 10.67%
2010 4.062.896 -7.02%
2011 4.330.363 6.18%
2011 4.330.363 0%
2012 4.978.634 13.02%
2013 5.834.994 14.68%
2014 5.914.469 1.34%
2015 5.600.520 -5.61%
2016 5.220.478 -7.28%
2017 4.489.124 -16.29%
2018 4.325.774 -3.78%
2019 3.980.970 -8.66%
2020 14.213.053 71.99%
2021 9.227.023 -54.04%
2022 8.324.714 -10.84%
2023 11.724.000 28.99%
2024 6.591.000 -77.88%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Biomerica, Inc. Assets
Year Assets Growth
1986 7.500.000
1987 6.300.000 -19.05%
1988 4.800.000 -31.25%
1989 3.800.000 -26.32%
1990 9.000.000 57.78%
1991 7.300.000 -23.29%
1992 6.400.000 -14.06%
1993 6.300.000 -1.59%
1994 6.300.000 0%
1995 5.800.000 -8.62%
1996 6.100.000 4.92%
1997 7.400.000 17.57%
1998 7.500.000 1.33%
1999 7.800.000 3.85%
2000 6.735.309 -15.81%
2001 5.347.121 -25.96%
2002 5.276.626 -1.34%
2003 5.548.029 4.89%
2004 5.567.890 0.36%
2005 5.790.686 3.85%
2006 2.428.322 -138.46%
2007 3.224.508 24.69%
2008 5.107.711 36.87%
2009 5.152.072 0.86%
2010 5.015.200 -2.73%
2011 4.955.378 -1.21%
2011 4.955.378 0%
2012 5.570.922 11.05%
2013 6.394.887 12.88%
2014 6.470.313 1.17%
2015 6.124.453 -5.65%
2016 5.726.505 -6.95%
2017 5.017.990 -14.12%
2018 5.222.582 3.92%
2019 5.245.364 0.43%
2020 17.259.878 69.61%
2021 11.818.813 -46.04%
2022 11.374.280 -3.91%
2023 14.454.000 21.31%
2024 9.254.000 -56.19%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Biomerica, Inc. Liabilities
Year Liabilities Growth
1986 1.400.000
1987 1.700.000 17.65%
1988 700.000 -142.86%
1989 500.000 -40%
1990 4.400.000 88.64%
1991 4.800.000 8.33%
1992 4.100.000 -17.07%
1993 3.500.000 -17.14%
1994 3.000.000 -16.67%
1995 2.600.000 -15.38%
1996 2.000.000 -30%
1997 1.500.000 -33.33%
1998 1.300.000 -15.38%
1999 1.600.000 18.75%
2000 1.827.562 12.45%
2001 1.827.300 -0.01%
2002 1.981.028 7.76%
2003 2.302.129 13.95%
2004 2.054.316 -12.06%
2005 2.257.772 9.01%
2006 1.364.575 -65.46%
2007 1.471.956 7.3%
2008 1.223.763 -20.28%
2009 804.086 -52.19%
2010 952.304 15.56%
2011 625.015 -52.36%
2011 625.015 0%
2012 592.288 -5.53%
2013 559.893 -5.79%
2014 555.844 -0.73%
2015 523.933 -6.09%
2016 506.027 -3.54%
2017 528.866 4.32%
2018 896.808 41.03%
2019 1.264.394 29.07%
2020 3.046.825 58.5%
2021 2.591.790 -17.56%
2022 3.049.566 15.01%
2023 2.730.000 -11.71%
2024 2.663.000 -2.52%

Biomerica, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.32
Net Income per Share
-0.36
Price to Earning Ratio
-0.89x
Price To Sales Ratio
0.99x
POCF Ratio
-0.99
PFCF Ratio
-0.97
Price to Book Ratio
0.81
EV to Sales
0.36
EV Over EBITDA
-0.32
EV to Operating CashFlow
-0.36
EV to FreeCashFlow
-0.36
Earnings Yield
-1.12
FreeCashFlow Yield
-1.03
Market Cap
0,01 Bil.
Enterprise Value
0,00 Bil.
Graham Number
1.77
Graham NetNet
0.2

Income Statement Metrics

Net Income per Share
-0.36
Income Quality
0.9
ROE
-0.69
Return On Assets
-0.65
Return On Capital Employed
-0.9
Net Income per EBT
1.01
EBT Per Ebit
0.93
Ebit per Revenue
-1.18
Effective Tax Rate
-0.01

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.28
Stock Based Compensation to Revenue
0.15
Gross Profit Margin
0.11
Operating Profit Margin
-1.18
Pretax Profit Margin
-1.1
Net Profit Margin
-1.1

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.32
Free CashFlow per Share
-0.33
Capex to Operating CashFlow
-0.02
Capex to Revenue
0.02
Capex to Depreciation
0.31
Return on Invested Capital
-0.87
Return on Tangible Assets
-0.66
Days Sales Outstanding
63.86
Days Payables Outstanding
21.88
Days of Inventory on Hand
180.49
Receivables Turnover
5.72
Payables Turnover
16.68
Inventory Turnover
2.02
Capex per Share
0.01

Balance Sheet

Cash per Share
0,25
Book Value per Share
0,39
Tangible Book Value per Share
0.38
Shareholders Equity per Share
0.39
Interest Debt per Share
0.05
Debt to Equity
0.12
Debt to Assets
0.08
Net Debt to EBITDA
0.56
Current Ratio
3.51
Tangible Asset Value
0,01 Bil.
Net Current Asset Value
0,01 Bil.
Invested Capital
6682000
Working Capital
0,01 Bil.
Intangibles to Total Assets
0.02
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
2252500
Debt to Market Cap
0.15

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Biomerica, Inc. Dividends
Year Dividends Growth

Biomerica, Inc. Profile

About Biomerica, Inc.

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

CEO
Mr. Zackary S. Irani
Employee
64
Address
17571 Von Karman Avenue
Irvine, 92614

Biomerica, Inc. Executives & BODs

Biomerica, Inc. Executives & BODs
# Name Age
1 Mr. Zackary S. Irani
Chief Executive Officer & Director
70
2 Mr. Allen C. Barbieri
Executive Vice-Chairman of the Board & Corporate Secretary
70
3 Mr. Robert W. Carlson
Chief Commercial Officer
70
4 Ms. Lucy Liu Ph.D.
Director of Manufacturing & Technical Operations
70

Biomerica, Inc. Competitors